Case Study 2: The Cholesterol Simplification — When Patient Communication Became Bad Science

The Simplification

"Good cholesterol (HDL) vs. bad cholesterol (LDL)" is one of the most widely known medical simplifications. It shapes patient education, pharmaceutical marketing, clinical guidelines, and public understanding of cardiovascular risk.

The Complex Reality

The actual relationship between cholesterol and cardiovascular disease involves:

  • LDL particle size and density: Small, dense LDL particles appear more atherogenic than large, buoyant LDL particles. Total LDL level doesn't distinguish between these.
  • LDL particle number: The number of LDL particles may be a better predictor of risk than the total LDL cholesterol mass. Two people with the same LDL level can have very different particle counts.
  • HDL functionality: Not all HDL is equally protective. HDL's protective effect varies by individual and may not be causal — drugs that raise HDL have generally failed to reduce cardiovascular events.
  • Triglycerides: Triglyceride levels interact with both LDL and HDL in determining risk, adding a third dimension the good/bad binary ignores.
  • Inflammatory markers: C-reactive protein and other inflammatory markers may predict cardiovascular risk independently of cholesterol levels.
  • Individual genetics: The relationship between cholesterol levels and cardiovascular events varies by individual genetic profile.
  • Dietary response: Different individuals respond differently to dietary cholesterol — some are "hyper-responders" (significant LDL increase from dietary cholesterol) and some are "hypo-responders" (minimal change).

How the Simplification Became Bad Science

The good/bad cholesterol simplification began as a patient communication tool — a way to explain lipid panels in terms patients could understand. But over time, the simplification migrated from communication to science:

  1. Communication → Guidelines: The good/bad framework shaped clinical guidelines, which set LDL targets without accounting for particle size, particle number, or individual variation.
  2. Guidelines → Drug development: Pharmaceutical companies developed drugs targeted specifically at lowering LDL (statins) or raising HDL (CETP inhibitors) — targeting the simplified model rather than the complex reality.
  3. Drug development → Evidence base: Clinical trials tested whether drugs that changed the simplified numbers (lower LDL, higher HDL) improved outcomes. Statins (lower LDL) generally did. HDL-raising drugs generally didn't — suggesting that the "good cholesterol" half of the simplification was wrong.
  4. Evidence base → Updated guidelines: Guidelines were revised — but only partially. LDL targets remain the primary focus, despite evidence that the LDL number alone is a poor predictor for many individuals.

The Cost

The cholesterol simplification has contributed to: - Over-prescription of statins for individuals whose LDL level is elevated but whose actual cardiovascular risk is low (due to favorable particle profiles, strong HDL function, or low inflammation) - Under-treatment of individuals whose LDL level appears normal but whose particle profile is unfavorable - Billions of dollars spent on HDL-raising drugs that failed to improve outcomes - Public confusion about dietary cholesterol (eggs were demonized, then rehabilitated, then uncertain — all because the relationship was never as simple as the model claimed)

Discussion Questions

  1. The cholesterol simplification was useful for patient communication. At what point did it become destructive? Could the transition have been prevented?
  2. Apply the decision-relevance test: if clinicians used the complex model (particle size, number, inflammation) instead of the simplified model (total LDL), would treatment decisions change? For what proportion of patients?
  3. Design a lipid panel report that communicates both the simplified version and the complex version to physicians and patients.
  4. Compare the cholesterol simplification to the dietary fat simplification (Chapters 2, 5, 7, 9). How are the simplification mechanisms similar?

References

  • Superko, H. R. (2009). "Advanced Lipoprotein Testing and Subfractionation Are Clinically Useful." Circulation, 119(17), 2383–2395. (Tier 1)
  • Research on HDL functionality and the failure of HDL-raising drugs has been published extensively, including the AIM-HIGH and HPS2-THRIVE trials. (Tier 2)
  • Ravnskov, U. et al. (2018). "LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature." Expert Review of Clinical Pharmacology, 11(10), 959–970. (Tier 1 — a controversial but well-argued challenge to the LDL-centric model)